A PPARd agonist, GW0742, has been shown to reduce hyperglycemia-induced cardiac hypertrophy via ROS production suppression and further attenuation of Erk1/2 and PI3K/Akt signaling in case of hypertrophic stimuli [45]. Here, AKT1 is linked to cardiac hypertrophy.